Overcoming purification challenges in antibody therapeutics manufacturing with subdomain-specific affinity solutions
Sponsor
Since the first monoclonal antibody therapy was approved by the FDA in 1986, antibody engineering has dramatically evolved. Therapeutic antibodies have become the predominant class of biological drugs and are used to treat a variety of diseases including many types of cancer. With the development of novel bio-therapeutic antibody formats, such as bi-specific monoclonal antibodies, Fab fragments and Fc-fusion proteins, new purification challenges in the downstream process of these molecules arise.
With an altered or absent Fc-region, the use of bacterial surface proteins such as Protein A or L, is not always the most efficient solution for the purification of these novel modalities. Affinity chromatography resins, specifically developed to bind antibody subdomain regions, can provide an alternative solution in the purification process of a variety of antibody formats, thereby allowing commercial production of antibody therapeutics.
Attendees will learn:
- Learn more on antibody subdomain-specific affinity chromatography and how it can benefit the overall productivity of your purification workflow.
- Get real examples showcasing the use of these resins in the development of novel antibody therapeutics.
SPEAKERS
You might also like
Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process
Quality by design in mRNA manufacturing: at-line monitoring coupled with DOE for higher IVT yield and efficiency of purification
Scalable chromatographic strategies for mRNA and saRNA purification from IVT
From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development
